SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances raised full-year revenue guidance, reflecting strong demand for Amtagvi and Proleukin, is driving attention, with traders viewing it as evidence of improving commercial momentum. The reaction is broadly bullish, while many are also watching for upcoming NSCLC data; buyout and short-squeeze talk remains speculative.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

FHFA plans to let Fannie Mae and Freddie Mac use VantageScore alongside FICO in a simplified mortgage-pricing framework, raising concern that FICO could lose its longstanding edge in mortgage scoring and face pricing pressure. Traders are split between viewing the selloff as an overreaction given FICOs entrenched business and software operations, and fearing competition will erode its moat and growth.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQures four-year AMT-130 data for Huntingtons disease is driving attention: the primary cUHDRS measure showed disease slowing but missed statistical significance, while the TFC measure remained significant. Traders are split over whether the weaker long-term result threatens approval, with some arguing that the BLA review can still rely on the stronger three-year data and noting concerns about missing external-control data.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlists new ITC action against Micron, alleging infringement of HBM patents used in AI computing, is driving attention. Traders view the filing as added legal leverage and speculate about a settlement, while others caution that the outcome and timing are uncertain.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobiles new change-of-control severance policy has fueled buyout speculation, though traders disagree over whether it signals a potential deal or is routine governance; the policy alone does not confirm an acquisition. The chatter is also accompanied by frustration about the lack of a shipment or launch date for BlueBirds 1416.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

AstraZenecas strategic investment in Summit and a clinical collaboration to test ivonescimab with an AstraZeneca cancer drug are driving attention. Traders view the deal as financing support and a vote of confidence, while others caution it is not a buyout and does not resolve the separate FDA approval risk.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas selection for the U.S. Armys ALATTIS program to develop 10-kV silicon-carbide power semiconductors and a domestic manufacturing process is driving attention. Traders see the award as technology validation and a potential longer-term opportunity, while others note it is a prototype program with no disclosed financial terms or clear near-term revenue, and question whether the post-news gains can hold.

Carnival Corp. Ltd. engages in the operation of cruise ships. It operates through the following business segments: North America Cruise Operations, Europe Cruise Operations, Cruise Support, and Tour and Others. The North America Cruise Operations segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corporation Ltd.

Carnival Corp

Carnival is drawing attention ahead of quarterly results as traders debate whether elevated fuel costs tied to the Iran conflict will pressure its outlook. Bears worry about oil prices and Carnivals fuel exposure, while bulls view the steep selloff as excessive and look to earnings and resilient cruise demand for support.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

ZBCNs sharp gain has traders focused on a possible technical breakout, with posts citing resistance levels and renewed momentum. Some are also speculating about Robinhood or BlackRock ties, but those claims are unconfirmed; others point to Zebecs payroll and payment partnerships as longer-term support for the token.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Traders are focused on potential ANKTIVA label expansion for papillary bladder cancer, with the FDA decision date cited as January 6, 2027, and are also watching for trial and commercial updates. Optimism about upcoming catalysts and short-squeeze potential is balanced by frustration over delays, limited company news, and volatile trading.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


Jake71440

Jake71440